Clinical Trial Update: FRAGRANCE Part A Safety: Study to Find a Genetic Signature of de Novo Resistance to Letrozole [Phase 2]

View source ↗

Summary

A completed Phase 2 safety study investigating genetic signatures of de novo resistance to letrozole in breast cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• FEMARA (letrozole)

Snippet

Sponsor: Jules Bordet Institute | Conditions: Breast Cancer | Phase 2 | Status: COMPLETED